Neurocrine Biosciences, Inc.
12790 El Camino Real
479 articles with Neurocrine Biosciences, Inc.
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
Strategic partnership agreement provides Neurocrine Biosciences exclusive worldwide rights to early-to-mid-stage psychiatry pipeline compounds within Takeda’s Neuroscience portfolio
Neurocrine Biosciences is partnering with Japan’s Takeda Pharmaceutical to develop and commercialize molecules in Takeda’s early-to-mid-stage psychiatry pipeline.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Securities 2020 Napa Biopharma Conference at 2:00 p.m. PT (5:00 p.m. ET) on Monday, June 22, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
6/15/2020It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020
- Crinecerfont Demonstrates Meaningful Reductions in Key Disease Biomarkers After 14 Days of Treatment - Initiation of Global Registrational Study of Crinecerfont in Adults Planned for Second Half 2020 [08-June-2020] SAN DIEGO , June 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive data from its completed op
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on Thursday, June 11, 2020.
AbbVie won a first-of-its-kind approval for a non-surgical treatment aimed at treating heavy menstrual bleeding due to uterine fibroids, a common non-cancerous tumor, in pre-menopausal women.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.
With the COVID-19 pandemic closing physicians’ offices and causing patients to think twice about exposing themselves in healthcare settings, Neurocrine is delaying its launch of Ongentysis®.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the RBC Capital Markets 2020 Global Healthcare Conference at 3:40 p.m. ET on Tuesday, May 19, 2020.
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
New Analysis from Phase III BIPARK-1 Study Evaluate the Efficacy of Once-Daily ONGENTYS® (opicapone) Compared to Entacapone in Patients with Parkinson's Disease
Neurocrine Biosciences Exercises Option to License Idorsia's Novel Treatment for Rare Pediatric Epilepsy
Neurocrine Biosciences, Inc. and Idorsia Ltd announced, following Investigational New Drug application acceptance by the U.S. Food and Drug Administration, Neurocrine Biosciences has exercised its option to license the global rights of Idorsia's ACT-709478.
INGREZZA® (valbenazine) First Quarter Net Product Sales of $231 Million with Approximately 41,500 TRx
Neurocrine Biosciences, Inc. will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020.
Neurocrine Biosciences announced on Monday that it has received approval from the U.S. Food and Drug Administration for its once-daily oral drug, Ongentys, as an add-on treatment to levodopa/carbidopa for the treatment of Parkinson’s disease.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
- ONGENTYS, the First and Only Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa in Patients with Parkinson's Disease - Neurocrine Biosciences Plans to Make ONGENTYS Available to Patients Later This Year
Here’s a look at what’s on the U.S. Food and Drug Administration's schedule for the next two weeks.
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2020 Financial Results
Conference Call and Webcast Scheduled for Wednesday, May 6
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company's business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregivers, healthcare providers and employees.